tiprankstipranks
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
US Market
ASRT
Assertio Therapeutics
RESEARCH TOOLSreports
Want to see ASRT full AI Analyst Report?

Assertio Therapeutics (ASRT) Stock Forecast & Price Target

1,166 Followers
See the Price Targets and Ratings of:

ASRT Analyst Ratings

Moderate Buy
4Ratings
Moderate Buy
2 Buy
2 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Assertio
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ASRT Stock 12 Month Forecast

Average Price Target

$24.20
▲(34.37% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Assertio Therapeutics in the last 3 months. The average price target is $24.20 with a high forecast of $28.00 and a low forecast of $21.80. The average price target represents a 34.37% change from the last price of $18.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","29":"$29","13.25":"$13.25","18.5":"$18.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,13.25,18.5,23.75,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.47,19.20307692307692,19.936153846153847,20.66923076923077,21.40230769230769,22.135384615384616,22.86846153846154,23.60153846153846,24.334615384615383,25.067692307692308,25.80076923076923,26.533846153846156,27.266923076923078,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.47,18.91076923076923,19.35153846153846,19.79230769230769,20.233076923076922,20.673846153846153,21.114615384615384,21.555384615384614,21.996153846153845,22.436923076923076,22.877692307692307,23.318461538461538,23.75923076923077,{"y":24.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.47,18.726153846153846,18.982307692307693,19.23846153846154,19.494615384615383,19.75076923076923,20.006923076923076,20.263076923076923,20.51923076923077,20.775384615384617,21.03153846153846,21.287692307692307,21.543846153846154,{"y":21.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.91,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.24,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$24.20Lowest Price Target$21.80
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on ASRT
Naz Rahman
Maxim Group
Maxim Group
$21.8→$23.5
Hold
30.48%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (NASDAQ: ASRT), Aytu BioScience (NASDAQ: AYTU) and Oruka Therapeutics (NASDAQ: ORKA)
Lake Street Analyst forecast on ASRT
Thomas Flaten
Lake Street
Lake Street
$23.5
Hold
30.48%
Upside
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (NYSE: COR), LeonaBio (NASDAQ: LONA) and Assertio Therapeutics (NASDAQ: ASRT)
H.C. Wainwright Analyst forecast on ASRT
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$21.8
Buy
21.04%
Upside
Reiterated
05/05/26
Assertio price target raised to $21.80 from $18 at H.C. WainwrightAssertio price target raised to $21.80 from $18 at H.C. Wainwright
Alliance Global Partners Analyst forecast on ASRT
Unknown Analyst
Alliance Global Partners
Not Ranked
Alliance Global Partners
$28
Buy
55.47%
Upside
Reiterated
03/17/26
Alliance Global Partners Reaffirms Their Buy Rating on Assertio Therapeutics (ASRT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on ASRT
Naz Rahman
Maxim Group
Maxim Group
$21.8→$23.5
Hold
30.48%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (NASDAQ: ASRT), Aytu BioScience (NASDAQ: AYTU) and Oruka Therapeutics (NASDAQ: ORKA)
Lake Street Analyst forecast on ASRT
Thomas Flaten
Lake Street
Lake Street
$23.5
Hold
30.48%
Upside
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (NYSE: COR), LeonaBio (NASDAQ: LONA) and Assertio Therapeutics (NASDAQ: ASRT)
H.C. Wainwright Analyst forecast on ASRT
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$21.8
Buy
21.04%
Upside
Reiterated
05/05/26
Assertio price target raised to $21.80 from $18 at H.C. WainwrightAssertio price target raised to $21.80 from $18 at H.C. Wainwright
Alliance Global Partners Analyst forecast on ASRT
Unknown Analyst
Alliance Global Partners
Not Ranked
Alliance Global Partners
$28
Buy
55.47%
Upside
Reiterated
03/17/26
Alliance Global Partners Reaffirms Their Buy Rating on Assertio Therapeutics (ASRT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Assertio Therapeutics

3 Months
xxx
Success Rate
5/10 ratings generated profit
50%
Average Return
+10.08%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +10.08% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
8/10 ratings generated profit
80%
Average Return
+52.08%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +52.08% per trade.
2 Years
xxx
Success Rate
10/10 ratings generated profit
100%
Average Return
+79.01%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +79.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASRT Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
7
4
6
4
4
Buy
0
0
0
0
1
Hold
0
0
0
3
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
4
6
7
12
In the current month, ASRT has received 5 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ASRT average Analyst price target in the past 3 months is 24.20.
Each month's total comprises the sum of three months' worth of ratings.

ASRT Financial Forecast

ASRT Earnings Forecast

Next quarter’s earnings estimate for ASRT is -$0.36 with a range of -$1.88 to $0.28. The previous quarter’s EPS was -$2.93. ASRT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ASRT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ASRT is -$0.36 with a range of -$1.88 to $0.28. The previous quarter’s EPS was -$2.93. ASRT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ASRT has Performed in-line its overall industry.

ASRT Sales Forecast

Next quarter’s sales forecast for ASRT is $27.66M with a range of $16.59M to $34.30M. The previous quarter’s sales results were $9.93M. ASRT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ASRT has Performed in-line its overall industry.
Next quarter’s sales forecast for ASRT is $27.66M with a range of $16.59M to $34.30M. The previous quarter’s sales results were $9.93M. ASRT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ASRT has Performed in-line its overall industry.

ASRT Stock Forecast FAQ

What is ASRT’s average 12-month price target, according to analysts?
Based on analyst ratings, Assertio Therapeutics Inc’s 12-month average price target is 24.20.
    What is ASRT’s upside potential, based on the analysts’ average price target?
    Assertio Therapeutics Inc has 34.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ASRT a Buy, Sell or Hold?
          Assertio Therapeutics Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Assertio Therapeutics Inc’s price target?
            The average price target for Assertio Therapeutics Inc is 24.20. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.00 ,the lowest forecast is $21.80. The average price target represents 34.37% Increase from the current price of $18.01.
              What do analysts say about Assertio Therapeutics Inc?
              Assertio Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of ASRT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.